The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global JAK and PI3K Signaling Pathway Market Research Report 2024
Synopsis
Therapies related to the JAK and PI3K signaling pathways have the potential to target diseases such as cancer and inflammatory diseases, and no suitable drugs are currently available. Current therapies can reduce the burden of disease, but they cannot be cured.
The global JAK and PI3K Signaling Pathway market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Significant progress has been made in understanding the complexity of signaling pathways such as JAK and PI3K over the past few years. At the same time, great progress has been made in the isolation of target-specific therapies / inhibitors targeting abnormal signals in these pathways. After approval of ruxolitinib (for bone marrow fibrosis) and tofacitinib (for rheumatoid arthritis), the treatment of JAK and PI3K cell signaling pathways has focused on cancer lines and inflammatory diseases.
This report aims to provide a comprehensive presentation of the global market for JAK and PI3K Signaling Pathway, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding JAK and PI3K Signaling Pathway.
Report Scope
The JAK and PI3K Signaling Pathway market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global JAK and PI3K Signaling Pathway market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the JAK and PI3K Signaling Pathway companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer HealthCare Pharmaceuticals
AbbVie
AstraZeneca
Curis
Daiichi Sankyo
Exelixis
Genentech
Infinity Pharmaceuticals
Merck & Co.
Rigel Pharmaceuticals
TG Therapeutics
Sanofi Oncology
Vertex Pharmaceuticals
WILEX AG
Segment by Type
PI3K
Janus Kinase Therapies (Inhibitors)
PI3K Therapies (Inhibitors)
Signal Transduction Biomarkers for JAK and PI3K
Segment by Application
Cancer
Inflammatory Diseases
Cardiac Ailments
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of JAK and PI3K Signaling Pathway companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Therapies related to the JAK and PI3K signaling pathways have the potential to target diseases such as cancer and inflammatory diseases, and no suitable drugs are currently available. Current therapies can reduce the burden of disease, but they cannot be cured.
The global JAK and PI3K Signaling Pathway market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Significant progress has been made in understanding the complexity of signaling pathways such as JAK and PI3K over the past few years. At the same time, great progress has been made in the isolation of target-specific therapies / inhibitors targeting abnormal signals in these pathways. After approval of ruxolitinib (for bone marrow fibrosis) and tofacitinib (for rheumatoid arthritis), the treatment of JAK and PI3K cell signaling pathways has focused on cancer lines and inflammatory diseases.
This report aims to provide a comprehensive presentation of the global market for JAK and PI3K Signaling Pathway, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding JAK and PI3K Signaling Pathway.
Report Scope
The JAK and PI3K Signaling Pathway market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global JAK and PI3K Signaling Pathway market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the JAK and PI3K Signaling Pathway companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer HealthCare Pharmaceuticals
AbbVie
AstraZeneca
Curis
Daiichi Sankyo
Exelixis
Genentech
Infinity Pharmaceuticals
Merck & Co.
Rigel Pharmaceuticals
TG Therapeutics
Sanofi Oncology
Vertex Pharmaceuticals
WILEX AG
Segment by Type
PI3K
Janus Kinase Therapies (Inhibitors)
PI3K Therapies (Inhibitors)
Signal Transduction Biomarkers for JAK and PI3K
Segment by Application
Cancer
Inflammatory Diseases
Cardiac Ailments
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of JAK and PI3K Signaling Pathway companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global JAK and PI3K Signaling Pathway Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PI3K
1.2.3 Janus Kinase Therapies (Inhibitors)
1.2.4 PI3K Therapies (Inhibitors)
1.2.5 Signal Transduction Biomarkers for JAK and PI3K
1.3 Market by Application
1.3.1 Global JAK and PI3K Signaling Pathway Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Inflammatory Diseases
1.3.4 Cardiac Ailments
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global JAK and PI3K Signaling Pathway Market Perspective (2019-2030)
2.2 JAK and PI3K Signaling Pathway Growth Trends by Region
2.2.1 Global JAK and PI3K Signaling Pathway Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 JAK and PI3K Signaling Pathway Historic Market Size by Region (2019-2024)
2.2.3 JAK and PI3K Signaling Pathway Forecasted Market Size by Region (2025-2030)
2.3 JAK and PI3K Signaling Pathway Market Dynamics
2.3.1 JAK and PI3K Signaling Pathway Industry Trends
2.3.2 JAK and PI3K Signaling Pathway Market Drivers
2.3.3 JAK and PI3K Signaling Pathway Market Challenges
2.3.4 JAK and PI3K Signaling Pathway Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top JAK and PI3K Signaling Pathway Players by Revenue
3.1.1 Global Top JAK and PI3K Signaling Pathway Players by Revenue (2019-2024)
3.1.2 Global JAK and PI3K Signaling Pathway Revenue Market Share by Players (2019-2024)
3.2 Global JAK and PI3K Signaling Pathway Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by JAK and PI3K Signaling Pathway Revenue
3.4 Global JAK and PI3K Signaling Pathway Market Concentration Ratio
3.4.1 Global JAK and PI3K Signaling Pathway Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by JAK and PI3K Signaling Pathway Revenue in 2023
3.5 JAK and PI3K Signaling Pathway Key Players Head office and Area Served
3.6 Key Players JAK and PI3K Signaling Pathway Product Solution and Service
3.7 Date of Enter into JAK and PI3K Signaling Pathway Market
3.8 Mergers & Acquisitions, Expansion Plans
4 JAK and PI3K Signaling Pathway Breakdown Data by Type
4.1 Global JAK and PI3K Signaling Pathway Historic Market Size by Type (2019-2024)
4.2 Global JAK and PI3K Signaling Pathway Forecasted Market Size by Type (2025-2030)
5 JAK and PI3K Signaling Pathway Breakdown Data by Application
5.1 Global JAK and PI3K Signaling Pathway Historic Market Size by Application (2019-2024)
5.2 Global JAK and PI3K Signaling Pathway Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America JAK and PI3K Signaling Pathway Market Size (2019-2030)
6.2 North America JAK and PI3K Signaling Pathway Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America JAK and PI3K Signaling Pathway Market Size by Country (2019-2024)
6.4 North America JAK and PI3K Signaling Pathway Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe JAK and PI3K Signaling Pathway Market Size (2019-2030)
7.2 Europe JAK and PI3K Signaling Pathway Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe JAK and PI3K Signaling Pathway Market Size by Country (2019-2024)
7.4 Europe JAK and PI3K Signaling Pathway Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific JAK and PI3K Signaling Pathway Market Size (2019-2030)
8.2 Asia-Pacific JAK and PI3K Signaling Pathway Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Region (2019-2024)
8.4 Asia-Pacific JAK and PI3K Signaling Pathway Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America JAK and PI3K Signaling Pathway Market Size (2019-2030)
9.2 Latin America JAK and PI3K Signaling Pathway Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America JAK and PI3K Signaling Pathway Market Size by Country (2019-2024)
9.4 Latin America JAK and PI3K Signaling Pathway Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa JAK and PI3K Signaling Pathway Market Size (2019-2030)
10.2 Middle East & Africa JAK and PI3K Signaling Pathway Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Country (2019-2024)
10.4 Middle East & Africa JAK and PI3K Signaling Pathway Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer HealthCare Pharmaceuticals
11.1.1 Bayer HealthCare Pharmaceuticals Company Detail
11.1.2 Bayer HealthCare Pharmaceuticals Business Overview
11.1.3 Bayer HealthCare Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.1.4 Bayer HealthCare Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.1.5 Bayer HealthCare Pharmaceuticals Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Detail
11.2.2 AbbVie Business Overview
11.2.3 AbbVie JAK and PI3K Signaling Pathway Introduction
11.2.4 AbbVie Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.2.5 AbbVie Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca JAK and PI3K Signaling Pathway Introduction
11.3.4 AstraZeneca Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 Curis
11.4.1 Curis Company Detail
11.4.2 Curis Business Overview
11.4.3 Curis JAK and PI3K Signaling Pathway Introduction
11.4.4 Curis Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.4.5 Curis Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo JAK and PI3K Signaling Pathway Introduction
11.5.4 Daiichi Sankyo Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.5.5 Daiichi Sankyo Recent Development
11.6 Exelixis
11.6.1 Exelixis Company Detail
11.6.2 Exelixis Business Overview
11.6.3 Exelixis JAK and PI3K Signaling Pathway Introduction
11.6.4 Exelixis Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.6.5 Exelixis Recent Development
11.7 Genentech
11.7.1 Genentech Company Detail
11.7.2 Genentech Business Overview
11.7.3 Genentech JAK and PI3K Signaling Pathway Introduction
11.7.4 Genentech Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.7.5 Genentech Recent Development
11.8 Infinity Pharmaceuticals
11.8.1 Infinity Pharmaceuticals Company Detail
11.8.2 Infinity Pharmaceuticals Business Overview
11.8.3 Infinity Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.8.4 Infinity Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.8.5 Infinity Pharmaceuticals Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. JAK and PI3K Signaling Pathway Introduction
11.9.4 Merck & Co. Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.9.5 Merck & Co. Recent Development
11.10 Rigel Pharmaceuticals
11.10.1 Rigel Pharmaceuticals Company Detail
11.10.2 Rigel Pharmaceuticals Business Overview
11.10.3 Rigel Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.10.4 Rigel Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.10.5 Rigel Pharmaceuticals Recent Development
11.11 TG Therapeutics
11.11.1 TG Therapeutics Company Detail
11.11.2 TG Therapeutics Business Overview
11.11.3 TG Therapeutics JAK and PI3K Signaling Pathway Introduction
11.11.4 TG Therapeutics Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.11.5 TG Therapeutics Recent Development
11.12 Sanofi Oncology
11.12.1 Sanofi Oncology Company Detail
11.12.2 Sanofi Oncology Business Overview
11.12.3 Sanofi Oncology JAK and PI3K Signaling Pathway Introduction
11.12.4 Sanofi Oncology Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.12.5 Sanofi Oncology Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals JAK and PI3K Signaling Pathway Introduction
11.13.4 Vertex Pharmaceuticals Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 WILEX AG
11.14.1 WILEX AG Company Detail
11.14.2 WILEX AG Business Overview
11.14.3 WILEX AG JAK and PI3K Signaling Pathway Introduction
11.14.4 WILEX AG Revenue in JAK and PI3K Signaling Pathway Business (2019-2024)
11.14.5 WILEX AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
